Privium Fund Management’s Rocket Pharmaceuticals RCKT Stock Holding History

Privium Fund Management’s Portfolio RCKT Stock Details RCKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$835K	Buy	244,146 +2,000	+0.8%	+$6.65K	0.15%	46
2026 Q1	$867K	Buy	242,146 +72,000	+42%	+$286K	0.18%	46
2025 Q4	$597K	Sell	170,146 -262,614	-61%	-$899K	0.11%	48
2025 Q3	$1.41M	Hold	432,760	–	–	0.25%	36
2025 Q2	$1.12M	Hold	432,760	–	–	0.24%	30
2025 Q1	$2.89M	Buy	432,760 +35,110	+9%	+$347K	0.75%	21
2024 Q4	$5M	Buy	397,650 +102,850	+35%	+$1.55M	1.13%	19
2024 Q3	$5.44M	Buy	294,800 +43,820	+17%	+$898K	1.35%	21
2024 Q2	$4.96M	Buy	250,980 +15,930	+7%	+$366K	1.27%	23
2024 Q1	$6.33M	Buy	235,050 +2,000	+0.9%	+$56.8K	1.69%	18
2023 Q4	$6.87M	Buy	233,050 +89,700	+63%	+$1.98M	1.92%	16
2023 Q3	$2.94M	Buy	143,350 +84,000	+142%	+$1.53M	0.87%	29
2023 Q2	$1.19M	Hold	59,350	–	–	0.34%	44
2023 Q1	$1.02M	Hold	59,350	–	–	0.34%	39
2022 Q4	$1.16M	Buy	59,350 +9,600	+19%	+$177K	0.44%	33
2022 Q3	$698K	Buy	49,750 +25,000	+101%	+$390K	0.25%	53
2022 Q2	$341K	Buy	+24,750	New	+$295K	0.11%	73

Other funds holding RCKT

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Privium Fund Management's RCKT Position: Q2 2026 in Review

Privium Fund Management increased its Rocket Pharmaceuticals (RCKT) stake by 0.83% in Q2 2026, buying an estimated $6.65K and bringing the position to 244,146 shares worth $835K. The position accounts for 0.15% of the portfolio, ranked #46.

Privium Fund Management first reported a position in RCKT in Q2 2022 and has held it in 17 quarters since. The position peaked at $6.87M in Q4 2023. 180 funds tracked by Wall St. Rank hold RCKT as of Q2 2026.

Privium Fund Management held 244,146 shares of Rocket Pharmaceuticals worth $835K as of Q2 2026.
Privium Fund Management bought 2,000 Rocket Pharmaceuticals shares in Q2 2026, an estimated $6.65K.
Rocket Pharmaceuticals made up 0.15% of Privium Fund Management's portfolio in Q2 2026, its #46 holding.
Privium Fund Management first reported a position in Rocket Pharmaceuticals in Q2 2022 and has held it in 17 quarters since.
Privium Fund Management's Rocket Pharmaceuticals position peaked at $6.87M in Q4 2023.
180 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2026.

Based on Privium Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.